Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 366

1.

Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms.

Cho CS, Labow DM, Tang L, Klimstra DS, Loeffler AG, Leverson GE, Fong Y, Jarnagin WR, D'Angelica MI, Weber SM, Blumgart LH, Dematteo RP.

Cancer. 2008 Jul 1;113(1):126-34. doi: 10.1002/cncr.23523.

2.

Hepatic surgery for metastases from neuroendocrine tumors.

Sarmiento JM, Que FG.

Surg Oncol Clin N Am. 2003 Jan;12(1):231-42. Review.

PMID:
12735141
3.

Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection.

Guglielmi A, Ruzzenente A, Campagnaro T, Pachera S, Valdegamberi A, Nicoli P, Cappellani A, Malfermoni G, Iacono C.

World J Surg. 2009 Jun;33(6):1247-54. doi: 10.1007/s00268-009-9970-0.

PMID:
19294467
4.

Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach.

Saxena A, Chua TC, Sarkar A, Chu F, Liauw W, Zhao J, Morris DL.

Surgery. 2011 Feb;149(2):209-20. doi: 10.1016/j.surg.2010.06.008.

PMID:
20674950
5.

Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria.

Ueno S, Sakoda M, Kubo F, Hiwatashi K, Tateno T, Baba Y, Hasegawa S, Tsubouchi H; Kagoshima Liver Cancer Study Group..

J Hepatobiliary Pancreat Surg. 2009;16(3):359-66. doi: 10.1007/s00534-009-0069-7.

PMID:
19300896
6.

Hepatic neuroendocrine metastases: does intervention alter outcomes?

Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, Blumgart LH.

J Am Coll Surg. 2000 Apr;190(4):432-45.

PMID:
10757381
7.

Resection of noncolorectal nonneuroendocrine liver metastases: a comparative analysis.

Reddy SK, Barbas AS, Marroquin CE, Morse MA, Kuo PC, Clary BM.

J Am Coll Surg. 2007 Mar;204(3):372-82.

PMID:
17324770
8.

Liver-directed therapy for neuroendocrine neoplasm hepatic metastasis prolongs survival following progression after initial surgery.

Saxena A, Chua TC, Zhao J, Morris DL.

J Surg Oncol. 2012 Mar 15;105(4):342-50. doi: 10.1002/jso.22114.

PMID:
22006355
10.

Surgery for hepatic neuroendocrine tumors: a single institutional experience in Japan.

Hibi T, Sano T, Sakamoto Y, Takahashi Y, Uemura N, Ojima H, Shimada K, Kosuge T.

Jpn J Clin Oncol. 2007 Feb;37(2):102-7.

11.

[Liver resection for non-colorectal, non-neuroendocrine liver metastases--is hepatic resection justified as part of the oncosurgical treatment?].

Lehner F, Ramackers W, Bektas H, Becker T, Klempnauer J.

Zentralbl Chir. 2009 Sep;134(5):430-6. doi: 10.1055/s-0029-1224601. German.

PMID:
19757343
12.

Aggressive pancreatic resection for primary pancreatic neuroendocrine tumor: is it justifiable?

Teh SH, Deveney C, Sheppard BC.

Am J Surg. 2007 May;193(5):610-3; discussion 613.

PMID:
17434366
13.

Effect of postoperative morbidity on long-term survival after hepatic resection for metastatic colorectal cancer.

Ito H, Are C, Gonen M, D'Angelica M, Dematteo RP, Kemeny NE, Fong Y, Blumgart LH, Jarnagin WR.

Ann Surg. 2008 Jun;247(6):994-1002. doi: 10.1097/SLA.0b013e31816c405f.

PMID:
18520227
14.

Surgery and staging of pancreatic neuroendocrine tumors: a 14-year experience.

Ito H, Abramson M, Ito K, Swanson E, Cho N, Ruan DT, Swanson RS, Whang EE.

J Gastrointest Surg. 2010 May;14(5):891-8. doi: 10.1007/s11605-010-1173-3.

PMID:
20224984
15.

Metastatic neuroendocrine hepatic tumors: resection improves survival.

Musunuru S, Chen H, Rajpal S, Stephani N, McDermott JC, Holen K, Rikkers LF, Weber SM.

Arch Surg. 2006 Oct;141(10):1000-4; discussion 1005.

PMID:
17043278
16.

Necrosis and angioinvasion predict adverse outcome in pancreatic neuroendocrine tumors after curative surgical resection: results of a single-center series.

Demir R, Pohl J, Agaimy A, Peros G, Perrakis A, Merkel S, Hohenberger W, Klein P.

World J Surg. 2011 Dec;35(12):2764-72. doi: 10.1007/s00268-011-1262-9.

PMID:
21927963
17.

Liver transplantation for metastatic neuroendocrine tumors.

Lang H, Oldhafer KJ, Weimann A, Schlitt HJ, Scheumann GF, Flemming P, Ringe B, Pichlmayr R.

Ann Surg. 1997 Apr;225(4):347-54. Review.

18.

Metastectomy for non-colorectal, non-neuroendocrine liver secondaries.

Teo MC, Tan YM, Chung AY, Chow PK, Cheow PC, Soo KC, Hee SW, Ooi LL.

ANZ J Surg. 2006 Jul;76(7):575-8.

PMID:
16813621
19.

Predictors of survival after resection of early hepatocellular carcinoma.

Nathan H, Schulick RD, Choti MA, Pawlik TM.

Ann Surg. 2009 May;249(5):799-805. doi: 10.1097/SLA.0b013e3181a38eb5.

PMID:
19387322
20.

Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors.

Osborne DA, Zervos EE, Strosberg J, Boe BA, Malafa M, Rosemurgy AS, Yeatman TJ, Carey L, Duhaine L, Kvols LK.

Ann Surg Oncol. 2006 Apr;13(4):572-81. Erratum in: Ann Surg Oncol. 2006 Aug;13(8):1162. Strosberg, Jonathon [corrected to Strosberg, Jonathan].

PMID:
16511671
Items per page

Supplemental Content

Support Center